Theriva Biologics
TOVX
14 hedge funds and large institutions have $653K invested in Theriva Biologics in 2020 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 6 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% less ownership
Funds ownership: 0.03% → 0.03% (-0%)
8% less capital invested
Capital invested by funds: $707K → $653K (-$54K)
26% less funds holding
Funds holding: 19 → 14 (-5)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56.2K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$6.27K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$4.27K |
| 4 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$2.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$29K |
| 2 |
Renaissance Technologies
New York
|
-$15.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$13.5K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$10K |
| 5 |
William Blair & Company
Chicago,
Illinois
|
-$4.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $408K | -$15.9K | -119 | -3% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $59K | +$56.2K | +421 | +577% |
|
|
BCM
3
Bridgeway Capital Management
Houston,
Texas
| $52K | – | – | – |
|
|
4
Acadian Asset Management
Boston,
Massachusetts
| $35K | +$6.27K | +47 | +19% |
|
5
Fisher Asset Management
Camas,
Washington
| $29K | – | – | – |
|
|
6
William Blair & Company
Chicago,
Illinois
| $25K | -$4.4K | -33 | -14% |
|
7
BlackRock
New York
| $19K | – | – | – |
|
|
8
Northern Trust
Chicago,
Illinois
| $14K | +$4.27K | +32 | +39% |
|
9
Geode Capital Management
Boston,
Massachusetts
| $8K | – | – | – |
|
|
IA
10
IFP Advisors
Tampa,
Florida
| $2K | – | – | – |
|
|
GWM
11
Geneos Wealth Management
Englewood,
Colorado
| $2K | +$2.67K | +20 | New |
|
|
BFM
12
Boothbay Fund Management
New York
| – | -$29K | -225 | Closed |
|
|
13
UBS Group
Zurich,
Switzerland
| – | -$13.5K | -101 | Closed |
|
|
TSS
14
Two Sigma Securities
New York
| – | -$10K | -80 | Closed |
|
15
Fidelity Investments
Boston,
Massachusetts
| – | -$133 | -1 | Closed |
|
TOVX Hedge Fund Activity: Q3 2020 in Review
14 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2020, worth a combined $653K — down 7.6% from $707K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TOVX and 1 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $56.2K. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $29K sold.
- 14 institutional investors held Theriva Biologics (TOVX) as of Q3 2020, down from 19 in Q2 2020.
- Funds reported $653K of Theriva Biologics stock for Q3 2020, down 7.6% quarter-over-quarter.
- 1 fund opened new Theriva Biologics positions in Q3 2020 and 6 closed out, a net change of -5 holders.
- The largest Theriva Biologics buyer in Q3 2020 was Vanguard Group, an estimated $56.2K added.
- The largest Theriva Biologics seller in Q3 2020 was Boothbay Fund Management, an estimated $29K sold.
Based on aggregated 13F filings for Q3 2020.